InsiderTrades

Form 4 for NMRA Neumora Therapeutics, Inc.

Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001062993-23-022479 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MI 2023-12-12 2023-12-08 NMRA Burow Kristina Dir, 10% J - Other — +1.88M 4.13M +83% —
2023-12-12 2023-12-08 NMRA Burow Kristina Dir, 10% J - Other — +14.0K 27.6K +103% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-12-08 J A 703,061 — 1,387,228 I By ARCH Venture Fund VII, L.P. — — (F1) Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares. (F2) Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
2 Common Common Stock 2023-12-08 J A 13,997 — 27,617 D — — (F1) Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.
3 Common Common Stock 2023-12-08 J A 1,176,593 — 4,131,207 I By ARCH Venture Fund VIII Overage, L.P. — — (F1) Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares. (F3) Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.